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Abstract
The vascular system of the spinal cord is particularly complex and vulnerable. Damage to the main vessels or
alterations to the regulation of blood ﬂow will result in a reduction or temporary cessation of blood supply. The
resulting tissue hypoxia may be brief: acute, or long lasting: chronic. Damage to the vascular system of the spinal cord
will develop after a traumatic event or as a result of pathology. Traumatic events such as road trafﬁc accidents, serious
falls and surgical procedures, including aortic cross-clamping, will lead to an immediate cessation of perfusion, the
result of which may not be evident for several days, but may have long-term consequences including
neurodegeneration. Pathological events such as arterial sclerosis, venous occlusion and spinal cord compression will
result in a progressive reduction of blood ﬂow, leading to chronic hypoxia. While in some situations the initial
pathology is exclusively vascular, recent research in neurodegenerative disease has drawn attention to concomitant
vascular anomalies in disorders, including amyotrophic lateral sclerosis, spinal muscular atrophy and muscular sclerosis.
Understanding the role of, and tissue response to, chronic hypoxia is particularly important in these cases, where
inherent neural damage exacerbates the vulnerability of the nervous system to stressors including hypoxia.
Facts
● Damage to the spinal cord vascular system results in
acute or chronic hypoxia.
● Hypoxia causes progressive and irreversible damage,
which can be initially difﬁcult to detect.
● Hypoxia is damaging to neurones, especially those
already affected by intrinsic, neurological disease.
Open questions
● What is the effect of chronic hypoxia on the nervous
system?
● Is undiagnosed chronic hypoxia a causative or
confounding factor in neurodegenerative disease?
● Should the functionality of the spinal cord vascular
system be taken into account in the treatment of
neurodegenerative disease?
Background
Neurodegenerative diseases encompass a wide range of
disorders that have the deterioration and death of neu-
rones in the central nervous system (CNS) as a common
link. While often grouped together, the origin of the
pathology is highly variable, and may be intrinsic, due to
genetic factors, extrinsic, caused by external damage or a
combination of risk factors. Even within the same disease,
in cases like amyotrophic lateral sclerosis (ALS), there is a
broad array of mutated genes, such as SOD-1 or SEXT,
which result in the same symptomatology by which they
are then grouped1,2. While neurone-speciﬁc alterations
tend to be very disease speciﬁc, and research has shown
that frequently there is some sort of peripheral pathology
that exacerbates neural damage. For example, inﬂamma-
tion in ALS and multiple sclerosis, or microglial damage
in brain pathologies such as Alzheimer’s, aggravates the
underlying disease3,4. Recently, there has been signiﬁcant
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research into vascular damage and the role of hypoxia in
brain neurodegeneration in diseases such as Alzheimer’s
and other forms of dementia. This line of research has not
been explored in depth in relation to spinal cord neuro-
degeneration. However, the existing studies show great
potential to provide further understanding of disease
aetiology and risk factors, especially considering that they
are relevant to inherited disease and traumatic injury of
the spinal cord.
Spinal cord vascular system
Any research into the role of hypoxia in neurodegen-
eration in the spinal cord needs to consider whether the
hypoxia is acute or chronic (Table 1). Acute hypoxia is
short term, caused by a transient decrease in blood ﬂow to
an area, followed by a critical decrease in oxygen level. In
contrast, chronic hypoxia results from a long-term
reduction of normal oxygen levels5. Hypoxia studies also
need to take into account the complexity of the vascular
supply, and most importantly its particularly low efﬁ-
ciency6. The main vessel network develops during the ﬁrst
6 months of embryonic development, and then its layout
remains relatively unchanged to adulthood7. Extraspinal
vessels (chieﬂy branches of the aorta8) are responsible for
the majority of the blood ﬂow that arrives into the sys-
tem9. They connect with the intrinsic arterial system,
which can be divided into a central and a peripheral
system. The central system supplies mainly the grey
matter through the sulcal arteries, which are long-
itudinally connected by the anterior spinal artery10.
Depending on the type of radicular artery, they can also
feed the dura mater or the nerve roots close to them, and
sometimes they can be feeders of the anterior or posterior
spinal arteries11. The white matter is mostly supplied by
the peripheral system or pial network, which covers the
exterior of the spinal cord, from where they branch per-
pendicularly into the cord. Similarly to the sulcal arteries,
the pial network is connected longitudinally by the two
posterior spinal arteries10. The posterior and anterior
arteries are highly interconnected along the spinal cord at
a capillary level12, with the main point of contact being at
the termination of the cauda equina12,13 (Fig. 1).
The spinal cord is particularly vulnerable to damage
within the vascular network. While tissue oxygen levels at
the spinal cord are the same as the oxygen levels in the
brain (35–39mmHg), the blood ﬂow is between 40 and
60% lower11. The level of vulnerability may also vary
depending on the spinal cord section. The cervical area is
well supplied, and receives its main blood ﬂow coming
from radicular arteries branching from the vertebral and
subclavian arteries. The superior extent of the upper
anterior spinal artery is formed at this point by the union
of the vessels arising from each vertebral artery, while the
superior extent of the posterior spinal arteries are formed
by anastomoses between branches of the vertebral arteries
and posterior inferior cerebral arteries. The lower cervical
spinal cord is supplied by a vessel originating from the
deep cervical artery, which in turn originated from the
costocervical trunk that branches from the subclavian
artery14. The sacral sections have numerous connections
Table 1 Summary of the major causes of vascular damage to the spinal cord; the sites of initial damage and the long-
term consequences of that damage
Initial damage Consequences Key references
Hypoxia caused by
traumatic events
Acute spinal cord
hypoxia
Traumatic accidents (e.g. car accidents,
falls), surgery can cut temporarily blood
ﬂow to the spinal cord
Neural necrosis within 6 h and
up to 34–48 after hypoxic
episode. Long-lasting damage,
normally irreversible
Richards et al.23, Gravereaux
et al.24, Ahuja et al.25, Kato
et al.26, Long et al.38
Long-term spinal
cord compression
Damage to the spinal cord can result in
chronic compression of the spinal cord
paired with a prolonged decrease of
the blood supply
Decrease of vascular
microvasculature. Slow neural
damage, eventually irreversible
(after 9 weeks)
Cheng et al.37, Long et al.38,
Kurokawa et al.39, Kasahara
et al.40
Hypoxia due to
chronic disease
Vascular
alterations
Vascular pathology (e.g. arteriovenous
ﬁstulas) can result in a prolonged
decrease of the blood supply
Similar to spinal cord
compression. Shown to be
damaging to oligodendrocytes
(demyelination)
Hurst et al.49, Larsson et al.50,
Jellemaet al.51, Duncombe
et al.54, Shibata et al.57
Motor neurone
disease and
muscular sclerosis
Vascular anomalies have been detected
in some neurodegenerative diseases
(e.g. ALS, SMA), resulting in alterations
of the normal blood supply
Neural damage and
demyelination likely to be
increased. Potential negative
effect in neurone-focused
treatments
Somers et al.61, Zhong et al.62,
Nobutoki and Ihara63, Miyazaki
et al.64, Davies et al.72, Desai
et al. n.d., Hua et al.81
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to the lateral sacral arteries15. Both the thoracic and the
lumbar areas feed mainly from segmental arteries
branching directly from the aorta. However, the distance
between the main points of entry into the spinal cord
blood network is a lot greater in the thoracic area11.
The lower number of segmental arteries means that
occlusion of any artery feeding into the thoracic spinal
cord can potentially be signiﬁcantly more damaging than
in any other region, and that both the thoracic and lumbar
areas are far more at risk in the event of aortic occlusion
or damage. This is especially true of the artery of
Adamkiewicz, the main radicular artery of the spinal cord.
This artery branches from the aorta at a variable point in
the lumbar or thoracic region, but most frequently
between T9 and T12, and rather less frequently between
T5 and T8 or L1 and L2. It passes though the inter-
vertebral foramen, and makes a hairpin turn in the
anterior spinal cord, where it anastomoses with the
anterior spinal artery16. The occlusion of the artery of
Adamkiewicz has been frequently shown to result in
paraplegia17. Within the cord (Fig. 2), the capillary net-
work density is always much higher in grey matter com-
pared with white matter18. Grey matter artery density can
also vary, as it is correlated to the metabolic demand of
each region of the spinal cord19. Within grey matter, there
is a decrease in vascularity at the ends of the posterior
horns, their irrigation being decreased in comparison with
the rest of the grey matter11. As motor neurones are
situated in this area of lower vessel density, they are at
higher risk than other cells of being affected by any
alterations to the blood supply or any damage to the
microvasculature. A low vessel density increases the
likelihood of the collateral circulation being insufﬁcient to
protect the surrounding tissue from damage in the case of
loss of perfusion, and therby contributes to the higher
vulnerability of the tissue.
Haemodynamics are also highly complex, and can make
the consequences of vessel damage difﬁcult to predict.
Blood ﬂow can be ascending or descending within the
cord, which creates numerous watershed areas where
opposing currents meet20. Watershed areas have a higher
likelihood of becoming hypoxic during any event that
results in nearby areas being subjected to abnormal
pressure21. Again, this can be particularly damaging at the
thoracic region, where the larger distance between radi-
cular arteries results in larger watershed areas11. Blood
ﬂow can be regulated rapidly by mechanisms that regulate
blood and tissue pressure, even changing its direction, but
this regulation may not work correctly in an unhealthy
spinal cord. The fragility of this system needs to be taken
into consideration in cases of non-traumatic hypoxia.
Chronic near- or actual hypoxic conditions may mean
that any disease-related (acute) hypoxia may not induce a
normal protective response, and could potentially aggra-
vate degeneration due to improper regulation of cellular
processes.
Acute hypoxia in spinal cord traumatic injuries
Traumatic injuries are one of the main potential causes
of damage to the spinal cord. Spinal cord injuries affect
thousands of people every year, and their effect can last a
lifetime22. These injures are mainly caused by car acci-
dents or falls, as well as violence and sport-related acci-
dents, so they can affect a wide range of people23.
Similarly, surgery involving vessels that supply the spinal
cord, such as those clamped during surgery for thor-
acoabdominal aneurysms, generates a considerable risk of
damage due to ischaemia resulting from the operation,
with very similar consequences24. There are several fac-
tors in a traumatic injury that can lead to ischaemia in the
spinal cord. Both the decrease/loss of perfusion and also
autonomic nerve dysfunction can lead to loss of blood
pressure regulation and excessive relaxation/dilation of
blood vessels, generally resulting in acute hypotension. If
the damage is signiﬁcant and affects pulmonary function,
oxygen levels in blood may also be reduced25. Even after a
short (15–20min) episode of hypoxia, neural necrosis will
rapidly ensue within 6 h, and damaged cells will continue
to die from apoptosis for 24–48 h26. This last apoptotic
Fig. 1 The blood supply of the spinal cord originates mainly from
the aorta. The network of vessels that surround the cord is connected
by three main vessels: the anterior spinal artery and the two posterior
spinal arteries
Fig. 2 The three major blood vessels feed the medulla through the
peripheral and central systems
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stage can be greatly aggravated by the cytokine cascades
and microglia that were activated by the initial necrotic
cell damage27. Although this damage can be long lasting,
and normally irreversible, these changes due to acute
hypoxia can be triggered by a very short period of initial
hypoxic damage.
Chronic hypoxia due to vessel compression
While acute compression, which signiﬁcantly reduces
blood ﬂow, can have a very similar outcome to a spinal
cord injury28, chronic compression can be more difﬁcult to
detect but may still have long-term consequences. Chronic
compression has been hypothesised as the origin of several
myelopathies. Cervical myelopathies appear in elderly
individuals and are one of the most common spinal cord
disorders at late ages29. They are caused by compression of
the spinal cord canal, generally caused by degeneration or
abnormal ossiﬁcation of the ligaments and vertebrae30.
Unlike spinal cord injury, where the main damage is
related to the main vessels, the vascular hypothesis of this
disease considers damage to the microvasculature a more
likely cause of the ischaemia31. Other myelopathies in this
group include Surfer’s myelopathy, caused by hyper-
extension of the back due to the inadequate practice of the
sport32, or Hirayama disease, a disorder that appears as
progressive weakness and dysfunction of the upper body
and limbs in young people33,34. It is also possible for spinal
cord vascular compression to appear as a secondary effect
of metastatic tumours35. Taken together, the incidence of
these diseases is low; a study of Hirayama disease in Japan
found only 333 cases between 1996 and 199836, and the
prevalence of degenerative cervical myelopathy in the
United States has been estimated at 4.04/100,000 people
per year30. Consequently, most of the research on the
effects of long-term spinal cord compression has been
done in mouse models. Chronic compression has been
shown to result in a decrease of vascular density37, espe-
cially of the microvasculature38, and to a signiﬁcant
decrease in spinal cord blood ﬂow39. Damage of this kind
can be very slow to develop and will eventually cause
irreversible damage, but might be reversible if detected in
the early stages. Studies on rats showed that neural
damage could be recovered from when chronic compres-
sion was present for up to 6 weeks, but this capacity for
recovery disappeared if the compression lasted longer than
9 weeks40. While early diagnosis for early relief of the
compression would probably be the best option, for
example with surgery41, diagnosis tends to happen after
neurological symptoms have already appeared, which is by
deﬁnition too late. This applies both to arterial and venous
compression; while most research is focussed on the for-
mer, there is also related compression of the venous plexus
at the cauda equina, which could be correlated with neu-
rodegeneration, particularly with lumbar stenosis42–44.
Chronic hypoxia due to vascular alterations
Blood ﬂow to the spinal cord can also be altered by vas-
cular damage. These cases, while scarce, are particularly
interesting due to the damage being caused exclusively by
alterations of the blood ﬂow. Both traumatic injuries and
compression damage have a physical trauma factor that can
affect neuronal well-being and alter the normal state of the
surrounding tissue. The disarray of the normal blood dis-
tribution can have several causes. An unusual example
would be a case where a myelopathy developed due to
cholesterol-related arteriosclerosis45. Most cases are related
to arteriovenous malformations, the most common being
spinal–dural arteriovenous ﬁstulas, with a prevalence of
5–10 cases per million46. This disorder appears in the form
of vascular lesions at the spinal cord, sometimes due to
genetic diseases, and generally in the thoracic area47,48. The
lesions tend to result in alterations of normal blood ﬂow,
arterialisation of intramedullary veins and eventual ischae-
mia and necrosis49–51. This type of disease is frequently
misdiagnosed, due to the symptoms being nerve-related
(extremity weakness, pain and sensory malfunction48,52),
and therefore confused with other forms of degenerative
spinal disease48. While there is little research speciﬁc to
spinal cord in this area, lately it has become more relevant
in brain disease, particularly in small-vessel disease. Small-
vessel disease effects tend to be long term. It is considered
one of the main causes for vascular cognitive impairment,
and is related to about 45% of new dementia cases were
diagnosed globally every year53. Models for this disease
focusing on hypoperfusion of the nervous tissue have
shown that a decrease in the blood ﬂow results in chronic
hypoxia, particularly in the white matter54. It has also been
shown to cause alterations in the blood-brain barrier and
inﬂammation54–56. Particularly relevant for potential spinal
cord research is that chronic hypoxia has been shown to be
particularly damaging for oligodendrocytes and oligoden-
drocyte precursors, resulting in axon demyelination57.
Role of chronic hypoxia in motor neurone disease
and muscular sclerosis
Alterations of the vascular system have proven to be
sufﬁcient to trigger neural pathology, suggesting that
vascular alterations in diseases where neurones are
already affected by other factors could be exacerbating the
pathology. Two families of disease where this may be a
factor are amyotrophic lateral sclerosis (ALS) and spinal
muscular atrophy (SMA). Both of these diseases com-
monly have their origin in genetic defects, whether there
are several genes involved, as in ALS2, or just one, as in
SMA58. They overlap in several aspects of the patholo-
gies59,60, and vascular defects could also be a common
trait61–64. Alterations in the superoxide dismutase-1
(SOD-1) gene are correlated with 20% of familial and
2% of sporadic cases of ALS65, which are known to affect
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the vascular system, particularly the microvasculature62.
Histological analysis has shown alterations in the struc-
ture of the neurovascular unit64, which importantly, occur
prior to neurone damage62,64. This in turn suggests that
they may inﬂuence the onset of neurodegeneration in
ALS, especially since cell death has been linked to an
increase in hypoxia biomarkers66,67, and exposure to
intermittent hypoxia advances disease progression in
mouse models68. Similarly, histology of SMA spinal cords
has shown a signiﬁcant reduction in vascular density,
along with hypoxia in motor neurone cell bodies61. It has
also been speculated that astrocytic malfunction could
affect capillary blood ﬂow regulations, which along with
high levels of vasoconstrictor hormones could increase
the chances of chronic hypoperfusion63.
Besides ALS and SMA, there are other motor neurone
diseases where chronic hypoxia could be a factor. The role
of chronic hypoxia in axonal demyelination is of particular
interest in demyelinating disease like multiple sclerosis
(MS)69. Unlike ALS and SMA, the causes of MS are far
from clear, but are thought to be a mix of complex genetic
factors and external factors like Epstein–Barr virus
infecton70,71. Research done in MS shows that not only
can hypoxia result in damage following a similar pattern
to the lesions in early disease, but that an animal model
would show less damage under the same conditions if
supplied with highly oxygenated breathing air (80–95%
oxygen)72,73. This shows that chronic hypoxia likely plays
a role in the disease, which ﬁts with the ﬁndings of
decreased vascularity in the brain74, even if there is no
information about spinal cord vascularity. It also opens
the possibility of highly oxygenated air used as a treatment
to slow down the damage caused by MS.
These ﬁndings are likely also relevant in SMA, where a
novel treatment has been recently approved for patients.
SMA is the result of the homozygous mutation of the
SMN1 gene, resulting in a failure to produce the survival
motor neurone protein (SMN)58, which is necessary for
survival beyond the embryonic stage75. SMA only occurs
as a disease because of the existence of the survival motor
neurone 2 (SMN2) gene, which is identical to SMN1 save
for a single mutation at exon 7 that results in its exclusion
during splicing. Due to this variation, only a small amount
of functional SMN is produced by this SMN2 gene76.
Multiple copies of the SMN2 gene allow for a sufﬁcient
amount of SMN protein to be produced to ensure sur-
vival, but not to ensure full health. The treatment consists
of intrathecal injections of an antisense oligonucleotide
that promotes inclusion of exon 7 in SMN2, resulting in
higher levels of full-length SMN protein being produced
in patient cells. While promising, the delivery by intra-
thecal injections means that the vascular system remains
untreated77. SMA has always been considered a neuro-
degenerative disease, but SMN is a ubiquitous protein
that is expressed in every cell and tissue78. More recently,
considerable evidence has shown a signiﬁcant systemic
pathology61,79,80 that includes organ, blood cell and vas-
cular alterations. Given the ﬁndings of vascular dysfunc-
tion at a pre-symptomatic stage, and considering that this
treatment is delivered to very young children, future
damage caused by chronic dysfunction of perfusion can-
not be ignored. This is supported by mouse models of
acute SMA, where peripheral delivery of therapeutics has
been shown to be required for long-term effectiveness81.
Chronic and acute hypoxia response
In order to better predict the possible consequences of
spinal cord hypoxia on neurones, it is necessary to con-
sider the natural response of the organism to hypoxia. The
basis of the hypoxia response is relatively well known. It is
based on the promotor protein HIF1, whose activation
depends on the α-subunit of the protein that accumulates
when cellular oxygen levels fall82. HIF1 (Fig. 3) will trigger
the production of a wide range of proteins among whose
functions are regulation of apoptosis, metabolism and
angiogenesis83, in a response time that can be as short as
30 min84. However, the HIF1 response tends to have a
more signiﬁcant role in the response to acute hypoxia. Its
activation requires very low oxygen levels (around 1% O2),
and within a relatively short period of time, <72 h, it is
downregulated85. In chronic hypoxia, the main response
appears to come from a different HIF form: HIF-2α. This
protein appears during milder hypoxia (around 5% O2)
85
and remains active for a much longer period of time86
during which its major function seems to be in promoting
vascular development87 and increasing erythropoiesis88.
Understanding the nature of this response is especially
important in cases where the vascular system has already
been shown to malfunctioning51,62,64. In such cases, the
Fig. 3 Hypoxia induces a HIF-1 mediated cellular response that
involves a large range of cellular and systemic functions related to
neuronal survival
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main response of the organism to ameliorate damage may
be completely ineffective, especially in diseases like ALS,
where the HIF1 response has been shown to be defective
in monocytes, suggesting that the hypoxia molecular
response could be affected89. It has been shown that
dysregulation of HIF1 can result in a decrease of vascular
endothelial growth factor (VEGF) expression, with a
consequent decrease in angiogenesis90,91. Outside of dis-
ease, the main situation where an organism needs to adapt
to lower-than-normal oxygen conditions is related to
changes in altitude92. Research in this area has shown that
the ﬁrst response in the brain is to increase blood ﬂow93,
followed by an increase of red cell volume92 and an
increase in angiogenesis94. Assuming that the same pat-
tern occurs in the spinal cord, it is hard to say what could
happen in diseases where vascular development and blood
ﬂood regulation are already affected.
Conclusion
Research on neurodegeneration is frequently centred on
neurone-speciﬁc responses and processes. However, it is
necessary to remember that regulation of the environment
where the neurones are located depends signiﬁcantly on the
tissues surrounding them. Vascular tissue has been a sig-
niﬁcant focus for research in brain neurodegeneration95,96,
yet there is still little research in this area with respect to
spinal cord neurodegeneration. Considering the well-
established fact that poor blood distribution and ischaemia
alone can cause neural damage51, it is likely that the vascular
system in its entirety (heart, vessels and circulating cells) is a
factor that must be carefully considered in any neurode-
generative disease. This is especially relevant in diseases like
ALS or SMA, where neurones have already been debilitated
by other factors that increase their vulnerability to hypoxic
stress.
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